Saturday, January 06, 2018 11:01:44 AM
SANUWAVE has engaged in a range of preparatory activities to ensure it is ready for an imminent U.S. market release, including identifying and hiring the first tier of sales personnel; dialogue with targeted hospitals for initial adoption; and conducting early industry and patient awareness initiatives.
“With the FDA de novo order in place, we will now accelerate our U.S. sales process with strategic partnerships and the hiring of key sales personnel to begin initial, targeted market release in the U.S” said Mr. Richardson. “SANUWAVE is excited to advance our efforts to bring the dermaPACE System to the U.S. market.”
Recent SNWV News
- SANUWAVE Announces Record Quarterly Revenues: Q2 FY2024 Financial Results • InvestorsHub NewsWire • 08/13/2024 11:11:39 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 10:05:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:08:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:06:17 PM
- SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • InvestorsHub NewsWire • 08/08/2024 10:59:17 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/18/2024 08:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 08:05:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 11:05:40 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/08/2024 08:06:05 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 06/04/2024 11:06:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:05:34 AM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 06/03/2024 08:35:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:31:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 11:16:31 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:54:03 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 02/28/2024 10:03:27 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 02/21/2024 09:07:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:05:50 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/05/2024 11:09:04 AM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 01/25/2024 10:17:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:46:34 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 01/22/2024 09:45:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:05:36 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 01/03/2024 10:21:49 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM